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Abstract 
Growth factor-receptor interactions at the cell surface ventually leading to the transcriptional ctivation of immediate arly genes is mediated 
by the mitogen-activated protein kinase (MAP kinase/MAPK) cascade. Here we show that overexpression f extracellular signal-regulated kinase 
1 (ERK1) cDNA, encoding p44 ~'pk, results in the activation of Elk-l, the serum response factor accessory protein. We also show that overexpression 
of ERK2, encoding p42 m'pk, activates Myc, but not Elk-1. Therefore, the MAP kinase cascade diverges with at least one specific target for each MAP 
kinase isoform and provides a novel mechanism for differential regulation of this signaling pathway. 
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1. Introduction 
The initiation of mammalian cell proliferation by pep- 
tide growth factors involves a programmed series of 
events that are triggered following ligand-receptor in- 
teractions at the cell surface. The transduction of these 
signals from membrane receptors into the nucleus is me- 
diated by an evolutionarily conserved kinase cascade 
(reviewed in [1-3]). In these parallel signaling cascades, 
found in yeast, nematode, Drosophila, and mammals, it
appears that receptor protein tyrosine kinases activate a
common set of molecules that include mitogen-activated 
protein kinases (MAP kinases)/extracellular signal-regu- 
lated kinases (ERKs), MAP kinase/ERK-activating ki-
nase (also referred to as MEK, formerly known as MAP 
kinase activator), Raf protein kinase, p2 lr~s, guanine nu- 
cleotide releasing factors, src homology domains-con- 
taining adaptors and protein phosphatases (reviewed in 
[4-151). 
Although many of the biochemical details of the above 
signaling cascades are still vague, protein phosphoryla- 
tion by Raf, MEK, and MAP kinases are expected to 
play significant roles in regulating steps throughout these 
pathways. Ribosomal protein $6, which may be identi- 
cal to chromatin-associated pp33 [16], is a downstream 
target of this signaling cascade. This protein is 
phosphorylated byribosomal $6 kinase II (also referred 
to as p90~k), which in turn is activated after phosphoryl- 
ation by MAP kinase [17]. MAP kinase now consists of 
related 40-46 kDa kinases that are activated by a variety 
of extracellular ligands and can use microtubule-associ- 
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ated protein 2, myelin basic protein, and/or epidermal 
growth factor receptor as in vitro substrates. Recently, 
cDNAs encoding rat p44 ~pk (ERK1) and p42 mapk 
(ERK2), mouse p44 m~pk and p42 m~pk, human p40 mapk, 
p41 mapk, p42 m~pk and p44 ~pk were cloned [18-25]. Amino 
acid identity between p44 m~pk and p42 mapk is about 78%. 
Here we report the first functional difference between 
these two MAP kinases. 
In vitro studies with recombinant MAP kinases have 
shown that they possess a slow intrinsic auto- 
phosphorylation activity, and that auto-phosphorylation 
of tyrosine is accompanied by slow autoactivation [25- 
28]. This observation has led to a search for a MAP 
kinase activator which could stimulate MAP kinase au- 
tophosphorylation. Recent identification of MEK as a 
dual-specificity hreonine and tyrosine protein kinase for 
MAP kinases argues against his model [10,29-31]. Al- 
though autophosphorylation of MAP kinases may not 
be a physiological ctivation mechanism, the overexpres- 
sion of MAP kinase isoforms, even in the absence of 
upstream signal input, can help to resolve the function 
of individual MAP kinase in the signaling cascade. 
Efforts to correlate MAP kinase activity with growth 
factor-regulated gene expression have focused primarily 
on immediate arly genes (reviewed in [32]), which are 
rapidly and transiently transcribed upon serum stimula- 
tion of quiescent fibroblasts in culture. Recent evidence 
indicates that MAP kinases translocate from the cyto- 
plasm to the nucleus upon serum growth factor stimula- 
tion [33,34], consistent with a direct role of MAP kinases 
in the regulation of transcription factor activity. The 
serum response element (SRE) in many immediate 
early gene promoters mediates transcriptional ctivation 
in response to serum growth factors [35]. A ternary com- 
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plex of serum response factor (SRF) dimer and Ternary 
complex factor (TCF)/Elk-1 binds to the SRE of the c-fos 
proto-oncogene promoter [36,37]. Recently, TCF/Elk-1 
is found to be phosphorylated by MAP kinase [37-40]. 
Our present study shows that Elk-1 is specifically acti- 
vated by ERK1 expression. Another well characterized 
MAP kinase substrate is the product of the c-myc 
proto-oncogene [41-43]. In contrast to Elk-l, 
c-Myc is specifically activated by ERK2 expression. This 
identification of specific targets for related protein ki- 
nases hould lead to a better understanding ofhow these 
enzymes are orchestrated within a signaling network as 
well as provide a clearer picture on the dynamic aspects 
of cellular regulation in response to external stimuli. 
2. Materials and methods 
2.1. Plasmids 
The XmaI-EcoRI fragment of pBSERK1 [18] was subcloned into the 
pMex vector [44] to generate pMex-ERKI. The BamHI-EcoRI frag- 
ment from pMex-ERK1 was recloned into the pSVneoHMTII vector 
[45]. The EcoRI fragment ofpBluescript-ERK1 [23] was subcloned into 
the pUHD 10-3 vector [46]. Plasmid pCMV-ERK2 was a gift from 
Dr. Jeng-Homg Her and Dr. Michael Weber. Plasmids pGAIA-EIkC 
and pGAIA-EIkC A383 A389 mutant were gifts from Dr. Richard 
Treisman. Plasmids pGAL4-Myc and pGAL4-Myc A62 mutant were 
gifts from Dr. Roger Davis. Human collagenase promoter plasmid 
-91/-42 tk CAT4 [47] was a gift from Dr. Hans-Peter Auer and Dr. 
Peter Herrlich. 
2.2. Cell culture 
NIH/3T3 fibroblasts (American Type Culture Collection CRL 1658) 
A 
were grown in Dulbecco's modified Eagle's medium supplemented with 
10% fetal bovine serum (FBS). 
2.3. Transient DNA transfections and chloramphenicol acetyltransferase 
(CAT) assays 
DNA transfections and CAT assays were carried out as described 
previously [48]. fl-Galactosidase activity was used to normalize CAT 
activity. 
2.4. Stable DNA transfections and cadmium chloride induction 
DNA transfections by the calcium phosphate precipitation proce- 
dure and G418 selection have been described [49]. Pools of stable 
transfectants were screened for accumulation of ERK1 RNA in re- 
sponse to 5 #M cadmium chloride (CdC12) in the absence of serum. 
2.5. Western blot analysis 
NIH/3T3 fibroblasts were harvested 48 h after DNA transfection. 
Total cellular protein was fractionated by SDS-polyacrylamide g l elec- 
trophoresis and then transferred to a PVDF membrane for detection 
by 12CA5 monoclonal antibody [50], rabbit anti-mouse IgG and 
[125I]protein A.
3. Results 
Overexpression of p44 erkl MAP kinase was able to 
stimulate transcription of the collagenase promoter 
which contains a single activator protein 1 (AP1) site 
[51]. Therefore, this kinase may, directly [52,53] or indi- 
rectly [54,55], phosphorylate and activate c-Jun which 
binds the AP1 site. Another known promoter element 
which is likely downstream of the MAP kinase pathway 
is the c-fos SRE because Raf kinase, acting upstream of 
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Fig. 1. Constitutive or inducible xpression of p44 erkl stimulates transcription of the c-fos SRE. (Panel A) NIH/3T3 fibroblasts were transfected with 
9 #g DNA, including 1.5 #g of a CAT reporter plasmid (pFC53E or p-91/-42 tk CAT4), 0 or 6/zg MAP kinase expression plasmid (pMex-ERK1 
or pCMV-ERK2), 0 or 6/ag vector plasmid (pMex), and 1.5 #g fl-galactosidase expression plasmid (pCMVfl). Cells were serum-starved after DNA 
transfection. CAT activities were normalized for differences in transfection efficiency by measurement of the fl-galactosidase activity [48]. (Panel B) 
NIH/3T3 fibroblasts were transfected with 10 #g DNA, including 1/ag of a CAT reporter plasmid (pFC53E), 0 or 2#g MAP kinase xpression plasmid 
(pUHD 10-3/ERK1), 0 or 2/ag tTA expression plasmid (pUHD15-1), and 1 #g fl-galactosidase expression plasmid (pCMVfl). Cells were serum- 
starved after DNA transfection, and treated with 1/ag/ml tetracycline for 22 h. Cells not transfected with pUHD 10-3/ERK1 and pUHDI5-1 were 
harvested ( - serum), or stimulated with FBS (15% fnal) for 10 h (+ serum). CAT activities were normalized for differences in transfection efficiency 
by measurement of the fl-galactosidase activity [48]. 
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Fig. 2. Expression of p44 ~'1 stimulates the GAL4-EIkC transactivator. (Panel A) NIH/3T3 fibroblasts were transfected with 10/ag DNA, including 
1 /ag of a CAT reporter plasmid (pG5B CAT), 0.01 /ag of pGAL4-EIkC (GAL4-Elk), 0 or 0.4 or 0.8 or 2/ag MAP kinase expression plasmid 
(pMex-ERK1 or pCMV-ERK2), and 1/~g fl-galactosidase expression plasmid (pCMVfl). Cells were serum-starved after DNA transfection. CAT 
activities were normalized for differences in transfection efficiency by measurement of the fl-galactosidase activity [48]. (Panel B) NII-I/3T3 fibroblasts 
were transfected with 10/.tg DNA, including 1 ~tg of a CAT reporter plasmid (pG5B CAT), 0.01/ag of pGAL4-ElkC A383 A389 (GAL4-mElk), 
0 or 0.4 or 0.8 or 2/lg MAP kinase expression plasmid (pMex-ERK1 or pCMV-ERK2), and 1/ag ,8-galactosidase expression plasmid (pCMVfl). 
Cells were serum-starved after DNA transfection. CAT activities were normalized for differences in transfection efficiency by measurement of the 
fl-galactosidase activity [48]. Inset shows a Western blot of 250/tg protein from NIH/3T3 fibroblasts transfected with pCMV-ERK2 (lane 1) or 
untransfected (lane 2) fractionated by SDS-PAGE and probed with 12CA5 monoclonal antibody [50]. The arrow indicates the position of 42-kDa 
MAP kinase. 
containing this motif [58]. Furthermore, purified p44 erkl 
MAP kinase phosphorylates the conserved carboxyl-ter- 
minal transactivation domain of TCF [38] and Elk-1 [39] 
in vitro. Here we test whether expression of p44 erk~ MAP 
kinase can activate the c-fos SRE as well as the Elk-1 
transactivation domain in vivo. 
To express p44 ~rk~ MAP kinase, we constructed the 
following plasmids: rat cDNA encoding 367 residues of 
p44 ~k~ [18] was inserted into the pMex vector [44] under 
the control of the Moloney murine sarcoma virus long 
terminal repeat (Mo-MSV LTR) for constitutive expres- 
sion; and the full-length (380 aa) rat ERK1 cDNA [23] 
was inserted into the pUHD 10-3 vector [46] for tetracy- 
cline-inducible expression. As shown in Fig. 1A, cotrans- 
fection ofpFC53E [59], a c-fos SRE reporter plasmid, or 
human collagenase promoter [47] plasmid, with pMex- 
ERK1 described above, leads to a 7.2- or 3.4-fold stimu- 
lation in CAT activities, respectively. On the other hand, 
when the tetracycline-inducible p44 erkl MAP kinase ex- 
pression vector was cotransfected with pFC53E and 
pUHD15-1, encoding tetracycline-controlled transacti- 
vator (tTA) [46], CAT activities were stimulated over 
3-fold (Fig. 1B). 
Next, knowing that, in vitro, p44 erkt MAP kinase can 
phosphorylate Elk-1 [39], which associates with SRF to 
form the ternary complex over the c-fos SRE, we tested 
whether p44 ~rk~ MAP kinase expression can activate the 
Elk-1 transactivation domain that contains the putative 
MAP kinase phosphorylation sites [39]. Elk-1 does not 
bind DNA independently of SRF, therefore we assayed 
a reporter gene containing GAL4 binding sites, which is 
recognized by GAL4-Elk-1 fusion proteins. 
In quiescent fibroblasts, the activity of the GAL4-Elk- 
1 fusion protein was stimulated in a dose-dependent 
manner by increasing amounts of pMex-ERK1 DNA 
transfected (Fig. 2A). In contrast, similar amounts of 
pCMV-ERK2 DNA did not stimulate GAL4-Elk-1 ac- 
tivity. Expression of transfected hemagglutinin epitope- 
tagged ERK2 can be detected with 12CA5 antibody (Fig. 
2B, inset), consistent with its functional activity in vivo 
(see below). Both MAP kinase isoforms can phospho- 
rylate Elk-1 [39,40] but this may be due to a relaxed 
specificity of MAP kinases in vitro since additional thre- 
onine residues are phosphorylated compared with those 
labeled in vivo [40]. Finally, when the MAP kinase phos- 
phorylation sites (Ser 383 and Ser 389) were mutated to 
alanines, neither kinase could activate GAL4-Elk-1 (Fig. 
2B), showing that these serine residues of Elk- 1 are bona 
fide p44 erkl MAP kinase targets. 
To confirm the above results, we constructed an 
ERK1 expression plasmid under the control of the in- 
ducible human metallothionein II promoter. Since this 
plasmid also contains a neomycin phosphotransferase 
gene, G418-resistant s able transfectants were selected 
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after DNA transfection i to NIH/3T3 fibroblasts. In- 
duction of MAP kinase in these transfectants can lead to 
activation of the c-fos SRE [60]. The basal activity of the 
GAL4-EIk-1 fusion protein was similar in both ERK1 
transfectants and parental NIH/3T3 fibroblasts trans- 
fected with pGAL4-ElkC and pG5B CAT (Fig. 3). When 
ERK1 expression was induced by cadmium chloride, 
GAIA-EIk-1 activity was stimulated in serum-starved 
ERK1 transfectant (Fig. 3B), but not in quiescent NIH/ 
3T3 fibroblasts (Fig. 3A), presumably due to higher lev- 
els of MAP kinase in the transfectant cells. Endogenous 
MAP kinases in untransfected NIH/3T3 fibroblasts were 
activated by serum, not by cadmium chloride. Finally, 
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Fig. 3. Inducible expression of p44 ~kl stimulates the GAIA-EIkC 
transactivator. (Panel A) NIHI3T3 fibroblasts were transfected with 
10/zg DNA, including l gg of a CAT reporter plasmid (pG5B CAT), 
0.01 /zg of pGAIA-EIkC (GAL4-EIk) or pGALA-EIkC A383 A389 
(GAIA- mElk), and I ggfl-galactosidase expression plasmid (pCMVfl). 
Cells were serum-starved after DNA transfection. Control induction 
with metal ion were carried out with cadmium chloride (5 gM) for 16 
h. Serum stimulated ceils were treated with FBS (15% final) for 10 h. 
CAT activities were normalized for differences intransfection efficiency 
by measurement of the fl-galactosidase activity [48]. (Panel B) NIH/3T3 
fibroblasts tably transfected with pSVneoI-IMTII-ERKI were trans- 
fected with I0/tg DNA, including l gg of a CAT reporter plasmid 
(pG5B CAT), 0.01 gg of pGAIA-EIkC (GAL4-EIk) or pGAIA-EIkC 
A383 A389 (GAL4-mEIk), and I gg/~-galactosidase expression plasmid 
(pCMVfl). Cells were serum-starved after DNA transfection. Human 
metallothionein II promoter was induced with cadmium chloride 
(5 gM) for 16 h. Serum stimulated cells were treated with FBS (15% 
final) for 10 h. CAT activities were normalized for differences in trans- 
fection efficiency by measurement of the fl-galactosidase activity [48]. 
GAL4-Elk-1 without the ERK1 phosphorylation sites 
(as defined above) cannot be activated by cadmium chlo- 
ride or serum in either cell line. 
The novel result hat is presented above is that ERK2 
expression failed to activate GAL4-EIk-1. This result 
suggests that p44 e~kl and p42 ~r~ MAP kinases have spe- 
cific target substrates. To identify a specific downstream 
effector for p42 °rk2 MAP kinase, we tested whether only 
the latter can activate c-Myc. Seth and coworkers [43] 
have demonstrated that p42 ~rk2 MAP kinase expression 
can activate GAIA-Myc but they did not test the latter 
in response to p44 ~rki MAP kinase expression. We also 
showed that ERK2 expression can induce GAL4-Myc 
activity in quiescent fibroblasts (Fig. 4A). However, 
ERK1 expression, either under the control of the consti- 
tutive Mo-MSV LTR or the tetracycline-inducible pro- 
moter of pUHD 10-3, could not stimulate GAL4-Myc 
activity (Fig. 4B). Finally, mutation of the Myc MAP 
kinase phosphorylation site (Ser 62) to alanine results in 
a loss of its ability to be activated by p42 *rk2 MAP kinase. 
The above results demonstrate that the two MAP kinases 
have specific downstream targets. 
4. Discussion 
Based on the conservation of the MAP kinase signal- 
ing cascade throughout metazoan evolution, this path- 
way is important for the regulation of gene expression i
response to many extracellular signals. However, the 
downstream events occurring after MAP kinase activa- 
tion are far from clear. In order to achieve specificity in 
signal transduction, there are two main alternative r g- 
ulatory mechanisms: either functionally redundant MAP 
kinases act at a branch point in the kinase cascade to 
phosphorylate multiple proteins in response to both pro- 
liferation and differentiation signals; or the pathway ac- 
tually bifurcates after MEK so that individual MAP ki- 
nase targets different transcription factor and/or kinase 
substrate(s). Our data favors the latter possibility since 
we have identified specific downstream targets for p44 °rk~ 
and p42 erk2 MAP kinases. Nonetheless, our present data 
do not exclude the possibility that they can share com- 
mon targets, e.g. p90 rsk. 
Our results indicate that p44 e~kl and p42 erk2 MAP ki- 
nases are not functionally redundant. We demonstrate 
here, for the first time, that p44 ~kt MAP kinase specifi- 
cally activates the SRF-associated transcription factor 
Elk-l, and p42 erk2 MAP kinase specifically activates the 
immediate early gene product c-Myc. Proliferation and 
differentiation signals trigger intracellular effectors that 
converge on the MAP kinase cascade. Then p44 "~k~, 
p42 ~rk2, and p46 j"k [55] appears to act at a branch point 
in the signaling cascade to phosphorylate and activate 
specific transactivators. Such target specificities of MAP 
kinases will provide multiple sites for regulation inputs 
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Fig. 4. Expression of p44 ~I does not stimulate the GAIA-Myc transactivator. (Panel A) NII-I/3T3 fibroblasts were transfected with I0 gg DNA, 
including l/tg of a CAT reporter plasmid (pG5B CAT), 0.02 gg of pGAL41Myc (GAIA-Myc), 0 or 0.8 or 1.6 or 4 gg MAP kinase xpression plasmid 
(pCMV-ERK2), and l gg fl-galactosidase expression plasmid (pCMVff). Cells were serum-starved after DNA transfection. CAT activities were 
normalized for differences in transfection efficiency by measurement of the fl-galactosidase activity [48]. (Panel B) NIH/3T3 fibroblasts were 
transfected with 10/tg DNA, including I gg of a CAT reporter plasmid (pG5B CAT), 0.02 gg of pGAIAIMyc (GAL4-Myc) or pGAIAl[Ala62]Myc 
(GAIA-Myc-S62A), 0 or 2 gg MAP kinase expression plasmid (pMex-ERKl or pCMV-ERK2) or 2/~g MAP kinase expression plasmid pUHD 
10-3/ERKI (tERKI) and 2/~g tTA expression plasmid (pUHDl5-1), and I ggfl-galactosidase expression plasmid (pCMVfl). Cells were serum-starved 
after DNA transfection. CAT activities were normalized for differences in transfection efficiency by measurement of he fl-galactosidase activity [48]. 
(e.g. MEK versus protein kinase C) and signal integra- 
tion (e.g. growth stimuli versus differentiation signals). 
In the budding yeast Saccharomyces cerevisiae, genetic 
analyses of the mating response pathway predict an or- 
dered cascade of five kinases: STE20, STEll, STE7, 
FUS3 and KSS1 (reviewed in [61]). The MAP kinase 
homologues FUS3 and KSS1 act upstream of the tran- 
scription factor STE12. However, FUS3 and KSS1 differ 
in that only FUS3 is required for cell cycle arrest [62]. 
Furthermore, FAR1 protein is phosphorylated in re- 
sponse to 0t factor in kssl- mutant, but not infus3-,fus3- 
kssl-, or ste7- mutant [63]. The above observations indi- 
cate that FUS3, or alternatively, a kinase dependent on 
FUS3, mediates FAR1 phosphorylation [63,64]. There- 
fore, FUS3 and KSS1 may have both overlapping (e.g. 
phosphorylation f STE 12) and unique (e.g. phosphoryl- 
ation of FAR1 by FUS3) functions. As the yeast and 
mammalian kinase cascades are conserved in the order 
and sequence of the proteins, the regulatory mechanisms 
leading to the activation of their targets may also be 
similar. Consistent with the latter idea is our observation 
that ERK1 and ERK2 have unique functions. 
What are the structural determinants of MAP kinase 
substrate specificity? We noted that the MAP kinase 
phosphorylation site of Elk-1 (T_LSP) belongs to the 
XX(S/T)P class, whereas the phosphorylation site of 
c-Myc (PL_SP) has a PX(S/T)P motif [11]. If PX(S/T)P 
sites are phosphorylated specifically by p42 ~k2 MAP ki- 
nase, then p90 r~k may be another p42 erk2 MAP kinase 
target. On the other hand, Fos [65] and Jun [53], with 
XX(S/T)P sites, appear to be p44 erkl MAP kinase sub- 
strates. This hypothesis i being tested with GAL4-Jun 
and GmL4-[Leu63'73]Jun plasmids [66]. 
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